title: Recent progress on MAP kinase pathway inhibitors.
abstract: The RAS-RAF-MEK-ERK, or ERK signaling pathway propagates signals through an intracellular signal transduction cascade. Since approximately one third of human cancers are impacted by mutations in the ERK signaling pathway, intensive efforts to develop drugs targeting members of this cascade are ongoing. While efforts to develop drugs aimed at inhibiting RAS are still at an early stage, substantial progress in discovering clinical drugs targeting RAF, MEK, and ERK have been made. This review will highlight the recent progress in this area.
authors: Department of Drug Discovery, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada. Electronic address: david.uehling@oicr.on.ca.
authors: David E
authors: DE
authors: Uehling
authors: Pattern Recognition Receptor DPU, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, United States.
authors: Philip A
authors: PA
authors: Harris
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D015394:Molecular Structure; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors
keywords: B-RAF; ERK; Kinase; MAPK; MEK